As requested, on 10 August 2017, the Authority published a statement on the exposure assessment of bixin and norbixin [EFSA Journal 2017;15(8):4966.] as regards those revised uses and use levels. It concluded that the dietary exposure for bixin did not exceed the ADI in any exposure scenario. However, it concluded that the dietary exposure for norbixin exceeded the ADI at the high level (95th percentile) for toddlers and children in the two refined exposure scenarios (brand-loyal and non-brand-loyal exposure scenarios).
Recital 13, Regulation (EU) 2020/771
In forcesince 11 Jun 2020